AnaptysBio announces issuance of two new patents for SHM-XEL platform
AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, announced the issuance of patents in the US and Europe that provide additional coverage for its SHM-XEL platform. These patents extend AnaptysBio's leadership in the use of somatic hypermutation (SHM) for the discovery and optimization of antibodies and other proteins.
Read more on News-Medical-Net
Orignal From: AnaptysBio announces issuance of two new patents for SHM-XEL platform
Post a Comment